J ust as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment ...

Cognito’s headset uses light and sound therapy to stimulate gamma waves. Cognito Therapeutics The device, which looks like a blend of sunglasses and headphones, emits pulsing lights and sounds.

Kern sees potential for Cognito’s headset to be a standalone therapy or used alongside new Alzheimer’s drugs that target amyloid and which modestly slow the worsening of the disease.

Cognito finds new medical, technology heads in BrainStorm, Philips alums By Andrea Park Apr 17, 2023 11:15am Cognito Therapeutics executives chief medical officer Alzheimer's disease ...

(Cognito Therapeutics) The Hope study will task upwards of 400 people with mild to moderate Alzheimer’s with using the noninvasive device at home every day for 12 months, throughout which they ...

Cognito Therapeutics to Advance Digital Therapeutic for Alzheimer’s into Pivotal Studies Based on Positive Clinical Results Announced at AD/PD 2021 March 17, 2021 08:00 AM Eastern Daylight Time ...

Cognito, based in Cambridge, Mass., is developing a headset that feeds a patient light and sound to drive changes in the brains of people with Alzheimer’s disease and other neurological conditions.

The Phase 2 OVERTURE study (NCT03556280) is a randomized controlled trial (RCT) that demonstrated clinical benefits of Cognito’s proprietary gamma sensory stimulation device in mild-to-moderate ...